Results 231 to 240 of about 1,532,404 (358)

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Pharmacogenomics and risk stratification in cardiovascular care: Insights from randomized controlled trials. [PDF]

Medicine (Baltimore)
Khan SA, Khan S, Kausar H, Sharma P, Adhikari A, Parajuli SB, Bista M.   +6 more
europepmc   +1 more source

Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction

, 2002
Alexander P. Reiner, Susan R. Heckbert, Hans L. Vos, Robert A. S. Ariëns, Rozenn N. Lemaître, Nicholas L. Smith, Thomas Lumley, Thomas D. Rea, Lucia A. Hindorff, Gina D. Schellenbaum, Frits R. Rosendaal, David S. Siscovick, Bruce M. Psaty   +12 more
openalex   +1 more source

Genetic variability: The key problem in the prevention and therapy of RNA‐based virus infections [PDF]

, 2003
Magdalena Figlerowicz, Magdalena Alejska, Anna Kurzyńska‐Kokorniak, Marek Figlerowicz   +3 more
openalex   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

Genetic alterations of prostate cancer: in localized and metastatic prostate cancer. [PDF]

BMC Urol
Yoon CE, Kang S, Rhew SA, Kwon HJ, Shin D, Moon HW, Kim MY, Lee JY.   +7 more
europepmc   +1 more source

Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status [PDF]

, 2003
Debra Resta, Martin S. Tallman, Mary Beth Riley, John L. Frater, Brian J. Druker, LoAnn Peterson, Daina Variakojis, Mary Ann Hrisinko   +7 more
openalex   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source

Counseling supervision for genetic counselors: A proposed outsider witness structure. [PDF]

J Genet Couns
Ferrer-Duch M, Ulph F, Dachs Cabanas E, Fredman G, MacLeod R.   +4 more
europepmc   +1 more source

Genetic therapies, human genetic enhancement, and … eugenics? [PDF]

Gene Therapy, 2019
openaire   +2 more sources